226. 間質性膀胱炎（ハンナ型） ［臨床試験数：83，薬物数：122（DrugBank：44），標的遺伝子数：54，標的パスウェイ数：134］
Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03844412 | July 12, 2019 | 26 August 2019 | Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments | Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments | Vestibulodynia;Temporomandibular Disorder;Fibromyalgia Syndrome;Irritable Bowel Syndrome;Migraines;Tension Headache;Endometriosis;Interstitial Cystitis;Back Pain;Chronic Fatigue Syndrome | Drug: 5% lidocaine/5 mg/ml estradiol compound cream;Drug: Nortriptyline;Drug: Placebo cream;Drug: Placebo pill | Duke University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | 18 Years | 50 Years | Female | 400 | Phase 2 | United States |
| 2 | NCT04118946 | March 20, 2019 | 22 October 2019 | Platelet Enriched Plasma for Treatment of Interstitial Cystitis | Intra Vesical Instillation Versus Submucosal Injection of Platelet Enriched Plasma for Treatment of Interstitial Cystitis/Bladder Pain Syndrome: A Randomized Controlled Trial | Interstitial Cystitis;Bladder Pain Syndrome;Platelet Enriched Plasma | Biological: platelet enriched plasma | Mansoura University | Recruiting | 18 Years | N/A | Female | 33 | Phase 1/Phase 2 | Egypt | |
| 3 | NCT03463915 | January 25, 2019 | 18 March 2019 | Clinical Trial Comparing Two Bladder Instillations for IC/BPS | Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: Bladder instillation WITH triamcinolone acetonide;Drug: Bladder instillation WITHOUT triamcinolone acetonide | Olivia Cardenas-Trowers, M.D. | Recruiting | 18 Years | N/A | Female | 80 | Phase 3 | United States | |
| 4 | NCT03844581 | January 1, 2019 | 4 March 2019 | Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial Cystitis | Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial Cystitis | Interstitial Cystitis | Device: interferential current;Drug: Propiverine Hydrochloride | Cairo University | Not recruiting | 25 Years | 40 Years | Female | 40 | N/A | Egypt | |
| 5 | NCT03143920 | November 1, 2017 | 26 November 2018 | Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder | Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder: A Feasibility Trial | Chronic Interstitial Cystitis;Painful Bladder Syndrome;Recurrent Urinary Tract Infection | Combination Product: Hyperbaric Oxygen Therapy- | University of California, San Diego | Recruiting | 35 Years | 70 Years | Female | 40 | Early Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | JPRN-UMIN000029113 | 2017/10/10 | 2 April 2019 | Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis | Patients with interstitial cystitis | Ingestion of test food including fermented buckwheat sprouts (12 weeks, 4 tablets / once a day) | Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka | Kageyama Hospital (Shizuoka city) Nakamura Hospital (Beppu city) | Not Recruiting | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan | |
| 7 | NCT03282318 | September 28, 2017 | 11 June 2019 | A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome;Interstitial Cystitis | Drug: Placebo;Drug: ASP6294 | Astellas Pharma Europe B.V. | Not recruiting | 18 Years | N/A | Female | 117 | Phase 2 | Belgium;Czechia;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom | |
| 8 | EUCTR2016-004138-12-DE | 26/09/2017 | 19 November 2018 | Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects. | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis | Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0 Level: LLT Classification code 10071166 Term: Bladder pain syndrome System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP6294 Pharmaceutical Form: Solution for injection INN or Proposed INN: Not applicable Current Sponsor code: ASP6294 Other descriptive name: ASP6294 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Astellas Pharma Europe B.V. | Authorised | Female: yes Male: no | 163 | Phase 2 | Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom | |||
| 9 | NCT03463499 | September 22, 2017 | 23 April 2019 | The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients | The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients | Interstitial Cystitis | Drug: Hyaluronic Acid and Chondroitin Sulfate | Samsung Medical Center | Recruiting | 20 Years | N/A | All | 62 | N/A | Korea, Republic of | |
| 10 | JPRN-JapicCTI-173566 | 25/5/2017 | 16 July 2019 | Phase III study of KRP-116D | A Phase III, multicenter, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of KRP-116D in Japanese patients with interstitial cystisis. | Interstitial cystitis( IC ) | Intervention name : KRP-116D INN of the intervention : dimethyl sulfoxide Dosage And administration of the intervention : 50 mL intravesical instillation once every two weeks Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : 50 mL intravesical instillation once every two weeks | Kyorin Pharmaceutical Co.,LTD | Not Recruiting | 20 | BOTH | 90 | Phase 3 | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT02870738 | April 21, 2017 | 30 September 2019 | Bladder Directed vs. Pelvic Floor Therapy in IC/BPS | Comparison of Bladder Directed and Pelvic Floor Therapy in Women With Interstitial Cystitis/Bladder Pain Syndrome | Cystitis, Interstitial;Painful Bladder Syndrome | Procedure: Pelvic Floor Physical Therapy;Drug: Bladder Instillations | William Beaumont Hospitals | Baylor College of Medicine | Recruiting | 18 Years | 85 Years | Female | 128 | Phase 2 | United States |
| 12 | NCT03104361 | April 2017 | 16 December 2017 | Platelet-Rich Plasma (PRP) Injection in Treatment of Interstitial Cystitis | Intravesical Injections of Platelet-Rich Plasma (PRP) in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Clinical Trial | Interstitial Cystitis | Biological: Platelet-Rich Plasma | Buddhist Tzu Chi General Hospital | Not recruiting | 20 Years | N/A | All | 30 | Phase 1 | Taiwan | |
| 13 | NCT03008382 | March 1, 2017 | 29 July 2019 | Interstitial Cystitis: Examination of the Central Autonomic Network | Interstitial Cystitis: Examination of the Central Autonomic Network | Interstitial Cystitis/Painful Bladder Syndrome;Myofascial Pelvic Pain | Drug: Metoprolol Tartrate Oral Tablet;Drug: Placebo Oral Tablet | Medical College of Wisconsin | NorthShore University HealthSystem;Case Western Reserve University | Recruiting | 18 Years | 80 Years | Female | 180 | Phase 4 | United States |
| 14 | NCT02787083 | August 2016 | 14 October 2019 | A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis | A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis | Cystitis, Interstitial | Drug: Mirabegron;Drug: Placebo | Philadelphia Urosurgical Associates | Astellas Pharma Global Development, Inc. | Not recruiting | 18 Years | 95 Years | Female | 9 | Phase 3 | United States |
| 15 | JPRN-UMIN000027918 | 2016/07/01 | 2 April 2019 | Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitis | interstitial cystitis | heparin-lidocaine intravesical therapy | Department of Urology and Renal transplantation, Nagasaki University Hospital | Recruiting | 20years-old | 80years-old | Male and Female | 30 | Not selected | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT02858453 | July 2016 | 11 June 2018 | Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period | Interstitial Cystitis;Bladder Pain Syndrome;Painful Bladder Syndrome;Chronic Interstitial Cystitis | Drug: AQX-1125 100 mg;Drug: AQX-1125 200 mg;Drug: Placebo | Aquinox Pharmaceuticals (Canada) Inc. | Not recruiting | 18 Years | 80 Years | All | 433 | Phase 3 | United States;Belgium;Canada;Czechia;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;Czech Republic | |
| 17 | NCT03693001 | June 1, 2016 | 9 October 2018 | HBOT for Patients With IC/FM (Interstitial Cystitis/Fibromyalgia) | Clinical and Morphological Effects of Hyperbaric Oxygen Therapy in Patients With Interstitial Cystitis Associated With Fibromyalgia | Fibromyalgia;Interstitial Cystitis | Device: Intermittent Exposure to Oxygen via Oro-Nasal Mask | University of South Florida | University of Padova | Not recruiting | 18 Years | N/A | All | 12 | N/A | |
| 18 | JPRN-UMIN000026714 | 2016/02/26 | 2 April 2019 | RCT study of bladder instillation therapy in patients with refractory interstitial cystitis. | Interstitial cystitis | Treated with vesical instillation with heparin and alkalized lidocaine. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation. Treated with vesical instillation with heparin alone. As introduction therapy, patients will recieve instillation every 1 to 2 weeks for six times. Then maintenance therapy follows with 6 times of monthly instillation. | Department of Urology, Mitsui Memorial Hospital | Not Recruiting | 20years-old | Not applicable | Male and Female | 20 | Phase 2,3 | Japan | ||
| 19 | NCT02497976 | December 15, 2015 | 11 June 2018 | Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis | Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis | Cystitis, Interstitial | Biological: Certolizumab pegol;Drug: Placebo | ICStudy, LLC | UCB Pharma | Not recruiting | 18 Years | 65 Years | Female | 42 | Phase 3 | United States |
| 20 | EUCTR2015-004495-30-FI | 14/12/2015 | 28 December 2015 | Safety of intravesical bladder instillations among patients with severe interstitial cystitis | Safety of intravesical bladder instillations among patients with severe interstitial cystitis | Interstitial cystitis and bladder pain syndrome MedDRA version: 18.1 Level: LLT Classification code 10071166 Term: Bladder pain syndrome System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 18.1 Level: PT Classification code 10011796 Term: Cystitis interstitial System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12] | Trade Name: SANDIMMUN Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: CICLOSPORIN CAS Number: 59865-13-3 | Oulu University Hospital | Authorised | Female: yes Male: yes | Finland | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT02591199 | September 2015 | 23 July 2018 | Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis;Bladder Pain Syndrome | Drug: URG101;Drug: Placebo;Drug: Lidocaine;Drug: Heparin | Urigen | Not recruiting | 18 Years | N/A | All | 92 | Phase 2 | United States | |
| 22 | NCT01393223 | July 21, 2015 | 12 November 2018 | Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome | A Single-Center, Double-Blind, Randomized, Dose-Ranging, Placebo Controlled Trial Comparing the Safety, Tolerability and Efficacy of LP-08 With Placebo in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | Interstitial Cystitis | Drug: LP-08 80mg;Drug: Normal saline;Drug: LP-08 20mg | Lipella Pharmaceuticals, Inc. | William Beaumont Hospitals | Not recruiting | 18 Years | 70 Years | All | 21 | Phase 2 | United States |
| 23 | NCT02395042 | April 30, 2015 | 29 January 2018 | A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions | A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions | Cystitis, Interstitial;Ulcer | Drug: LiRIS®;Drug: LiRIS Placebo | Allergan | Not recruiting | 18 Years | N/A | Female | 62 | Phase 2 | United States;Canada | |
| 24 | NCT03076762 | March 2015 | 16 December 2017 | Comparative Study Suburothelial and Trigonal Botulinum Toxin A Injection in Treatment of Interstitial Cystitis | Comparative Study of the Efficacy and Safety Between Suburothelial and Trigonal Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Randomized, Clinical Trial | Bladder Pain Syndrome | Drug: intravesical onabotulinumtoxinA injection | Buddhist Tzu Chi General Hospital | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | Taiwan | |
| 25 | NCT02517996 | February 2015 | 15 July 2019 | Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) | Use of Preemptive Pudendal Nerve Block Prior to Hydrodistension for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): a Prospective, Double-blinded, Randomized Control Trial | Interstitial Cystitis;Painful Bladder Syndrome | Drug: Lidocaine;Drug: Placebo | Johns Hopkins University | Not recruiting | 18 Years | N/A | Female | 18 | N/A | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT02297100 | December 2014 | 11 June 2018 | Intravesicular Onabotulinumtoxin A in Interstitial Cystitis | The Impact of Injection Location on the Efficacy of Intravesicular Onabotulinumtoxin A in Interstitial Cystitis--Phase 4 | Interstitial Cystitis | Drug: Onabotulinumtoxin A;Procedure: injections upper aspect of trigone of urinary bladder;Procedure: injections on posterior bladder wall excluding the trigone | Wake Forest University Health Sciences | Allergan | Not recruiting | 18 Years | 80 Years | Female | 27 | Phase 4 | United States |
| 27 | NCT02247557 | September 2014 | 16 December 2017 | Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis | Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis — a Randomized, Double-blind, Placebo-controlled, Prospective Study | Interstitial Cystitis | Drug: Liposome encapsulated BoNT-A;Drug: BOTOX 200U in normal saline;Drug: Normal saline | Buddhist Tzu Chi General Hospital | Not recruiting | 20 Years | 80 Years | All | 90 | Phase 2 | Taiwan | |
| 28 | JPRN-UMIN000009197 | 2014/07/01 | 2 April 2019 | Safety and efficacy of tramadol in the treatment of refractory pain of interstitial cystitis: a double-blind, placebo-controlled, randomized prospective study | interstitial cystitis | oral administration of Tramadol after randomization oral administration of placebo after randomization | Departmen of Urology, The University of Tokyo Hospital | Not Recruiting | 20years-old | 80years-old | Male and Female | 90 | Not applicable | Japan | ||
| 29 | NCT01990898 | November 2013 | 16 December 2017 | Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action | Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action | Interstitial Cystitis | Drug: Cyclosporine | The Cleveland Clinic | Not recruiting | 18 Years | 80 Years | All | 26 | Phase 2 | United States | |
| 30 | NCT01879683 | July 2013 | 19 October 2017 | A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions | A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS® 400 mg in Women With Ulcerative Interstitial Cystitis | Chronic Interstitial Cystitis | Drug: LiRIS® 400 mg | Allergan | TARIS Biomedical, Inc. | Not recruiting | 18 Years | N/A | Female | 10 | Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT01882543 | June 2013 | 16 December 2017 | Efficacy and Safety of AQX-1125 in IC/BPS | A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway | Interstitial Cystitis;Bladder Pain Syndrome | Drug: AQX-1125;Drug: Placebo | Aquinox Pharmaceuticals (Canada) Inc. | Not recruiting | 18 Years | 75 Years | Female | 69 | Phase 2 | United States;Canada | |
| 32 | NCT01813565 | March 20, 2013 | 15 July 2019 | The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome. | The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome. | Interstitial Cystitis | Drug: Hyaluronic acid/chondroitin sulfate | Asan Medical Center | Not recruiting | 20 Years | N/A | All | 15 | N/A | Korea, Republic of | |
| 33 | NCT01824303 | March 2013 | 19 October 2017 | Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis | A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension | Interstitial Cystitis | Drug: LiRIS 400 mg;Other: LiRIS Placebo | Allergan | TARIS Biomedical, Inc. | Not recruiting | 18 Years | N/A | Female | 31 | Phase 2 | United States;Canada |
| 34 | JPRN-JMA-IIA00113 | 27/02/2013 | 2 April 2019 | Multi-center clinical study on the effect of glycine for disorders of urine storage | Multi-center clinical study on the effect of glycine for disorders of urine storage | Overactive bladder, chronic prostatitis, interstitial cystitis, and nocturia | Intervention type:DRUG. Intervention1:glycine, Dose form:POWDER, Route of administration:ORAL, intended dose regimen:Oral administration of Glycine 3g, twice a day, for 8 weeks . Control intervention1:glucose, Dose form:POWDER, Route of administration:ORAL, Intended dose regimen:Oral administration of Glucose 3g, twice a day, for 8 weeks . | Kimio Sugaya (Kitakami Central Hospital, and Southern Knights' Laboratory LLP) | Okinawa Kyodo Hospital, Kawahara Nephro-urology Clinic, Yamada Urologic Clinic, Akita Urologic Clinic, Kobe Medical Center, Kitanodai Clinic, Yokohama Motimachi Womens' Clinic LUNA, Nanbu Tokushukai Hospital, Okinawa Kokubu Hospital | Not Recruiting | >=20 YEARS | No Limit | BOTH | 160 | NOT APPLICABLE | Japan |
| 35 | NCT01048177 | December 2012 | 19 February 2015 | A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia | A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia | Vulvodynia | Drug: Bladder instillation with heparin/ lidocaine | Scripps Health | Not recruiting | 18 Years | 80 Years | Female | 0 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT01969773 | December 2012 | 16 December 2017 | Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment | Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial | Interstitial Cystitis | Drug: Botulinum toxin A;Drug: Normal saline instillation | Buddhist Tzu Chi General Hospital | Not recruiting | 20 Years | 85 Years | All | 60 | Phase 2 | Taiwan | |
| 37 | NCT01678911 | August 2012 | 19 October 2017 | Efficacy of Gralise® for Chronic Pelvic Pain | Efficacy of Gralise® for Chronic Pelvic Pain | Irritable Bowel Syndrome;Ulcerative Colitis;Interstitial Cystitis;Prostatitis;Pelvic Pain | Drug: Gralise | Shirley Ryan AbilityLab | Not recruiting | 18 Years | N/A | All | 11 | Phase 4 | United States | |
| 38 | JPRN-UMIN000008484 | 2012/07/23 | 2 April 2019 | a | Interstitial cystitis/ Hypersensitive bladder syndrome | Administration of mirabegron 50mg per day for four weeks. | Department of Urology, Graduate school of medicine, University of Tokyo | Not Recruiting | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan | ||
| 39 | NCT01731470 | July 2012 | 19 October 2017 | Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) | Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) | Interstitial Cystitis;Pelvic Pain | Biological: Liposomes | Kenneth Peters, MD | William Beaumont Hospitals | Not recruiting | 18 Years | N/A | All | 14 | N/A | United States |
| 40 | NCT01613586 | May 31, 2012 | 28 January 2019 | A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis | Cystitis, Interstitial;Urinary Bladder Disease;Pain;Urologic Diseases | Drug: ASP3652;Drug: Placebo | Astellas Pharma Europe B.V. | Not recruiting | 18 Years | N/A | Female | 287 | Phase 2 | Belgium;Czechia;Denmark;Germany;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Czech Republic | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | EUCTR2011-004555-39-BE | 07/05/2012 | 21 August 2017 | A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH | Bladder Pain Syndrome / Interstitial Cystitis MedDRA version: 14.1 Level: LLT Classification code 10071166 Term: Bladder pain syndrome System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1 Level: LLT Classification code 10008928 Term: Chronic interstitial cystitis NOS System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1 Level: LLT Classification code 10008927 Term: Chronic interstitial cystitis System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1 Level: PT Classification code 10011796 Term: Cystitis interstitial System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Product Name: ASP3652 Product Code: ASP3652 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ASP3652 Other descriptive name: ASP3652 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: ASP3652 Product Code: ASP3652 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ASP3652 Other descriptive name: ASP3652 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Astellas Pharma Europe B.V. | Not Recruiting | Female: yes Male: no | 300 | Phase 2 | Portugal;Spain;Lithuania;Russian Federation;Italy;France;Czech Republic;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands | |||
| 42 | NCT02000401 | May 2012 | 19 February 2015 | Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain | To Evaluate the Efficacy, Tolerability, and Safety of Intranasal Ketorolac Tromethamine (Sprix) as an Option for Acute (up to 5 Days) Pain Management Adult Interstitial Cystitis Patients Experiencing a Flare of Pain | Interstitial Cystitis | Drug: Ketorolac Tromethamine | Citrus Valley Medical Research, Inc. | Not recruiting | 18 Years | 64 Years | Female | 15 | Phase 4 | United States | |
| 43 | NCT01569438 | April 13, 2012 | 15 July 2019 | The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome | Bladder Pain Syndrome | Drug: Gefapixant;Drug: Sugar Pill | Afferent Pharmaceuticals, Inc. | Not recruiting | 18 Years | 80 Years | Female | 74 | Phase 2 | United States | ||
| 44 | NCT01559961 | March 2012 | 19 February 2015 | Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome | A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis | Drug: TTI-1612 | Trillium Therapeutics Inc. | Not recruiting | 18 Years | 65 Years | Female | 28 | Phase 1 | Canada | |
| 45 | JPRN-UMIN000006387 | 2011/11/01 | 2 April 2019 | Clinical study on the intravesical instillation of heparin, lidocain and bicarbonate for the patients with interstitial cystitis | interstitital cystitis | Intravesical instillation of heparin, lidocain and bicarbonate | University of Tokushima | Not Recruiting | Not applicable | Not applicable | Male and Female | 30 | Phase 2 | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT01475253 | November 2011 | 19 October 2017 | Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis | A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® in Women With Interstitial Cystitis Followed by an Open Label Extension | Interstitial Cystitis | Drug: Lidocaine Releasing Intravesical System - LiRIS®;Other: LiRIS Placebo;Procedure: Sham Cystoscopy Procedure | Allergan | TARIS Biomedical, Inc. | Not recruiting | 18 Years | N/A | Female | 104 | Phase 2 | United States;Canada |
| 47 | NCT01378754 | June 2011 | 19 February 2015 | Evaluate The Effectiveness Of Fospropofol (Lusedra®) For Induction Of Anesthesia | A DOSE RANGING STUDY TO EVALUATE THE EFFECTIVENESS OF FOSPROPOFOL (LUSEDRA®) FOR INDUCTION OF ANESTHESIA FOR OUTPATIENT UROLOGIC HYDRODILATION THERAPY | Interstitial Cystitis | Drug: Fospropofol (Lusedra®) 6.5;Drug: Fospropofol (Lusedra®) 10;Drug: Fospropofol (Lusedra®) 12 | Grace Shih, MD | Not recruiting | 18 Years | 65 Years | Both | 0 | N/A | United States | |
| 48 | NCT01295814 | March 2011 | 19 October 2017 | Efficacy Study of Adalimumab to Treat Interstitial Cystitis | An Investigator Initiated, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Humira® (Adalimumab) For The Treatment of Interstitial Cystitis(IC) | Interstitial Cystitis | Drug: Adalimumab;Other: inactive drug | ICStudy, LLC | Abbott | Not recruiting | 18 Years | 65 Years | All | 43 | Phase 3 | United States |
| 49 | EUCTR2010-021556-25-IT | 24/02/2011 | 23 December 2013 | Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS) Ascolta Trascrizione fonetica Dizionario - Visualizza dizionario dettagliato - IBSA 01-2010 | Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS) Ascolta Trascrizione fonetica Dizionario - Visualizza dizionario dettagliato - IBSA 01-2010 | Interstitial Cystitis MedDRA version: 9.1 Level: HLGT Classification code 10018188 | Trade Name: RIMSO 50 Pharmaceutical Form: Bladder irrigation INN or Proposed INN: Dimethyl sulfoxide Concentration unit: g gram(s) Concentration type: equal Concentration number: .54- | IBSA | Not Recruiting | Female: yes Male: no | Phase 3 | Italy | ||||
| 50 | NCT01197261 | September 2010 | 5 November 2018 | OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS) | An Exploratory, Randomised, Double-blind, Placebo-controlled, Parallel Group, Pilot Study to Assess the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets (OXN PR) Compared to Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome. | Interstitial Cystitis;Painful Bladder Syndrome;Pain | Drug: Oxycodone naloxone prolonged release tablets;Drug: Placebo tablets | Mundipharma Research GmbH & Co KG | Not recruiting | 18 Years | N/A | Female | 120 | Phase 2 | Czechia;Germany;Hungary;Poland;United Kingdom;Czech Republic | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT01083979 | August 2010 | 19 October 2017 | Intravesical Liposomes for Ulcerative Cystitis | Intravesical Liposomes for Ulcerative Cystitis | Interstitial Cystitis | Drug: Liposomes | Kenneth Peters, MD | Not recruiting | 20 Years | N/A | All | 1 | N/A | United States | |
| 52 | NCT01150565 | July 2010 | 19 February 2015 | Safety Study of LiRIS in Interstitial Cystitis (IC) Patients | Phase 1B Pilot Safety Study of LiRIS-TM, A Novel Bladder Drug Delivery Platform in Patients With Interstitial Cystitis | Interstitial Cystitis | Drug: LiRIS low dose and LiRIS high dose | Allergan | TARIS Biomedical, Inc. | Not recruiting | 18 Years | N/A | Female | 18 | Phase 1 | Canada |
| 53 | NCT00919802 | June 2010 | 16 December 2017 | Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis | Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis | Interstitial Cystitis | Drug: Oxytocin;Other: Saline as a nasal spray | University of Alabama at Birmingham | Not recruiting | 19 Years | 65 Years | All | 25 | Phase 4 | United States | |
| 54 | EUCTR2009-014597-17-SE | 03/05/2010 | 3 December 2012 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) | Chronic pain including the pain of interstitial cystitis/painful bladder syndrome. MedDRA version: 12.0 Level: LLT Classification code 10008927 Term: Chronic interstitial cystitis | Product Name: Tanezumab Product Code: PF-04383119 Pharmaceutical Form: Solution for injection INN or Proposed INN: Tanezumab CAS Number: 880266-57-9 Current Sponsor code: PF-04383119 Other descriptive name: RN624, RI624 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: Tanezumab Product Code: PF-04383119 Pharmaceutical Form: Solution for injection INN or Proposed INN: Tanezumab CAS Number: 880266-57-9 Current Sponsor code: PF-04383119 Other descriptive name: RN624, RI624 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: Tanezumab Product Code: PF-04383119 Pharmaceutical Form: Solution for injection INN or Proposed INN: Tanezumab CAS Number: 880266-57-9 Current Sponsor code: PF-04383119 Other descriptive name: RN624, RI624 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | Not Recruiting | Female: yes Male: yes | 300 | Phase 2B | Finland;Spain;Belgium;Germany;Sweden | |||
| 55 | NCT01195116 | May 2010 | 19 October 2017 | Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis | Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis | Interstitial Cystitis | Drug: Dexmedetomidine;Drug: Normal Saline | University of Rochester | Not recruiting | 18 Years | N/A | All | 41 | Phase 4 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT01069263 | February 2010 | 19 February 2015 | Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial Cystitis | Comparison Between Hyperbaric Oxygen Therapy (HBOT) and Intravesical Dimethyl Sulfoxide (DMSO) Instillation for the Treatment of Interstitial Cystitis - a Prospective, Randomized Cross-over Trial | Interstitial Cystitis | Other: Hyperbaric Oxygen Therapy;Drug: DMSO | Assaf-Harofeh Medical Center | Recruiting | 18 Years | 85 Years | Both | 60 | N/A | Israel | |
| 57 | NCT00999518 | January 2010 | 19 February 2015 | A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome | A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Moderate To Severe Pain Associated With Interstitial Cystitis/ Painful Bladder Syndrome (IC/PBS) | Cystitis, Interstitial | Biological: Tanezumab;Other: Placebo | Pfizer | Not recruiting | 18 Years | N/A | Both | 222 | Phase 2 | United States;Belgium;Canada;Finland;Hong Kong;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;India;South Africa;Germany | |
| 58 | NCT01030640 | December 2009 | 19 February 2015 | Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected | A Phase 1, Randomized, Double- Blind (Sponsor-Open), Placebo-Controlled Study To Examine The Density Of Intraepidermal Nerve Fibers After A Single Subcutaneous Administration Of Tanezumab In Healthy Volunteers | Osteoarthritis Pain;Chronic Low Back Pain;Pain Due to Interstitial Cystitis | Other: placebo;Biological: tanezumab | Pfizer | Not recruiting | 18 Years | 55 Years | Both | 28 | Phase 1 | United States | |
| 59 | NCT01074567 | December 2009 | 19 February 2015 | DMSO Efficacy in IC/PBS Patients During and After Treatment | Efficacy of DMSO Cocktail Treatment in Interstitial Cystitis Patients During and After Treatment | Cystitis, Interstitial | Drug: DMSO cocktail | Assaf-Harofeh Medical Center | Recruiting | 18 Years | N/A | Female | 50 | N/A | Israel | |
| 60 | NCT01616992 | September 2009 | 19 February 2015 | Interstitial Cystitis: Elucidation of the Psychophysiologic and Autonomic Characteristics (ICEPAC) Study | Interstitial Cystitis: Elucidation of the Psychophysiologic and Autonomic | Interstitial Cystitis/Painful Bladder Syndrome;Myofascial Pelvic Pain | Drug: Bupivacaine | Case Western Reserve University | Not recruiting | 18 Years | 80 Years | Female | 200 | N/A | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | NCT00919113 | July 2009 | 19 October 2017 | Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome | A Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Effectiveness and Safety of Uracyst® Compared to Inactive Control in Subjects With Interstitial Cystitis/Painful Bladder Syndrome | Interstitial Cystitis;Painful Bladder Syndrome | Drug: 2% sodium chondroitin sulfate;Drug: Placebo | Watson Pharmaceuticals | Not recruiting | 18 Years | N/A | Female | 98 | Phase 2 | United States | |
| 62 | ChiCTR-TRC-13003938 | 2009-06-01 | 18 April 2017 | Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of randomized, double-blind, placebo-controlled trial | Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of randomized, double-blind, placebo-controlled trial | interstitial cystitis | group A:oral sildenafil;group B:oral placebo ; | The First Af?liated Hospital of Wenzhou Medical College | Not Recruiting | 35 | 55 | Both | group A:24;group B:24; | Post-market | China | |
| 63 | NCT01294878 | March 2009 | 19 February 2015 | Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome | Explorative Study on the Use of Omalizumab in Patients Suffering From Interstitial Cystitis/Painful Bladder Syndrome | Interstitial Cystitis;Painful Bladder Syndrome | Drug: omalizumab | IRCCS Policlinico S. Matteo | Not recruiting | 18 Years | N/A | Female | 3 | Phase 3 | Italy | |
| 64 | NCT00823030 | January 2009 | 26 October 2015 | Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis | Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis | Interstitial Cystitis | Procedure: Urodynamic study;Drug: Lidocaine;Other: Normal Saline | North Shore Long Island Jewish Health System | Not recruiting | 18 Years | 80 Years | Both | 0 | N/A | United States | |
| 65 | EUCTR2009-018118-21-DE | 31 March 2014 | not applicable | An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo in opioid-naïve Subjects suffering from severe pain due to Bladder Pain Syndrome. - not applicable | Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) MedDRA version: 14.1 Level: LLT Classification code 10008927 Term: Chronic interstitial cystitis System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 5/2.5 mg Product Code: OXN 5/2.5 mg PR Pharmaceutical Form: Prolonged-release tablet CAS Number: 124-90-3 Other descriptive name: OXYCODONE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5.0- CAS Number: 357-08-4 Other descriptive name: NALOXONE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Trade Name: Targinact 10 mg/5 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 10/5 mg Product Code: OXN 10/5 mg PR Pharmaceutical Form: Prolonged-release tablet CAS Number: 124-90-3 Other descriptive name: OXYCODONE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10.0- CAS Number: 357-08-4 Other descriptive name: NALOXONE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5.0- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Trade Name: Targinact 20mg/10 mg prolonged-release tablets Product Name: oxycodone/naloxone prolonged release tablets 20/10 mg Product Code: OXN 20/10 mg PR Pharmaceutical Form: Prolonged-release tablet CAS Number: 124-90-3 Other descriptive name: OXYCODONE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20.0- CAS Number: 357-08-4 Other descriptive name: NALOXONE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10.0- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use Trade Name: Targinact 5mg/2.5 mg prolonged-release tablets | Mundipharma Research GmbH & Co. KG | Not Recruiting | Female: yes Male: no | 70 | Czech Republic;Hungary;Germany;United Kingdom | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | NCT00739739 | August 2008 | 19 February 2015 | An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis | A Phase 2, 12 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof Of Concept Study Evaluating The Efficacy And Safety Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis/Painful Bladder Syndrome. | Interstitial Cystitis;Painful Bladder Syndrome | Drug: PD 0299685 at 15mg BID;Drug: PD 0299685 at 30mg BID;Drug: placebo for PD 0299685 | Pfizer | Not recruiting | 18 Years | N/A | Both | 161 | Phase 2 | United States;Canada;Denmark;Finland;France;Germany | |
| 67 | JPRN-UMIN000001253 | 2008/07/01 | 2 April 2019 | A randomized trial to asses the effects of hydrogen-rich dissolution water in patients with interstitial cystitis | Interstitial cystitis | The patients will be intervened with hydrogen dissolution water group (hydrogen group) 200ml every three times in a day in 2 months (56days). After that, the patients in hydrogen dissolution water group will be transferred to the additional intervention term after the end of intervention. And after that, the patients will be randomized to withdrawal terms for more 1 month with hydrogen dissolution water or with placebo water. The patients will be intervened with normal water (placebo group) 200ml every three times in a day in 2 months (56days) After that, the patients in placebo water group will be given hydrogen water for more 1 month. | Koushinkai Hospital | Not Recruiting | 20years-old | 80years-old | Male and Female | 30 | Phase 2,3 | Japan | ||
| 68 | EUCTR2008-001501-42-FI | 15/05/2008 | 19 March 2012 | Tacrolimus in the treatment of Painful Bladder Syndrome / Interstitial Cystitis | Tacrolimus in the treatment of Painful Bladder Syndrome / Interstitial Cystitis | Painful bladder syndrome / interstitial cystitis (PBS/IC) MedDRA version: 1 Level: LLT Classification code 10005063 Term: | Trade Name: Prograf Pharmaceutical Form: INN or Proposed INN: TACROLIMUS CAS Number: 104987113 | Jukka Sairanen | Authorised | Female: yes Male: yes | Finland | |||||
| 69 | NCT00601484 | March 2008 | 19 February 2015 | An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis | A Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof Of Concept Study Evaluating The Efficacy And Safety Of PF-04383119 For The Treatment Of Pain Associated With Interstitial Cystitis | Cystitis, Interstitial | Drug: PF-04383119;Drug: Placebo | Pfizer | Not recruiting | 18 Years | N/A | Both | 65 | Phase 2 | United States | |
| 70 | EUCTR2007-005164-27-NL | 22/02/2008 | 19 March 2012 | Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/ Interstitial Cystitis | Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/ Interstitial Cystitis | Interstitial Cystitis (IC) is a syndrome characterized by bladder pain associated with urgency, frequency, nocturia, dysuria and sterile urine. The patho-physiology remains largely unclear. No universally, effective, treatment exists. Botulinum toxin-A (BTX-A) inhibits the release of acetylcholine at the presynaptic cholinergic junction resulting in temporally muscle relaxation and bladder desensitisation. We explore the effects of intravesical injections with BTX-A in the treatment of IC. | Trade Name: Botox Pharmaceutical Form: Concentrate for solution for injection | research office urology VUmc | Authorised | Female: yes Male: yes | 12 | Netherlands | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | EUCTR2008-002421-37-DE | 1 May 2012 | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. | INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME. MedDRA version: 9.1 Level: LLT Classification code 10008927 Term: Chronic interstitial cystitis | Product Name: PD 0299685 Pharmaceutical Form: Capsule, hard CAS Number: 313651-33-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: PD 0299685 Pharmaceutical Form: Capsule, hard CAS Number: 313651-33-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | Not Recruiting | Female: yes Male: yes | 147 | Phase 2 | Finland;Germany;Denmark;France | ||||
| 72 | NCT00451867 | March 2007 | 19 February 2015 | A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . . | A Randomized Multicenter Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Mycophenolate Mofetil (CellCept) for the Treatment of Refractory Interstitial Cystitis (IC) | Interstitial Cystitis;Painful Bladder Syndrome | Drug: Mycophenolate Mofetil;Drug: Mycofenolate Mofetil (MMF);Drug: Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 18 Years | N/A | Both | 210 | Phase 3 | United States;Canada | |
| 73 | NCT00380783 | October 2006 | 19 February 2015 | Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis | Cystitis, Interstitial | Drug: AGN 203818 | Allergan | Not recruiting | 18 Years | N/A | Female | 2 | Phase 2 | United States | ||
| 74 | NCT00275379 | August 2006 | 19 February 2015 | Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Exploratory Study of Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis | Cystitis, Interstitial | Drug: ERB-041 | Wyeth is now a wholly owned subsidiary of Pfizer | Not recruiting | 18 Years | N/A | Female | 60 | N/A | United States;Austria;Germany | |
| 75 | NCT00317070 | April 2006 | 19 February 2015 | Trial Comparing Intravesical Cocktail With Intravesical Dimethyl Sulfoxide (DMSO) in Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC) | A Randomized Controlled Trial to Evaluate the Efficacy and Tolerability of Intravesical Cocktail and Comparison With Intravesical Dimethyl Sulfoxide (DMSO) for the Treatment of Painful Bladder Syndrome Including Interstitial Cystitis (PBS/IC) | Interstitial Cystitis;Bladder Diseases | Drug: dimethyl sulfoxide;Drug: IC Cocktail | Capital District Health Authority, Canada | Not recruiting | 18 Years | N/A | Both | 10 | Phase 2 | Canada | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | EUCTR2005-003367-23-DE | 13/02/2006 | 19 March 2012 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0 Level: LLT Classification code 10008928 | Product Name: YM672 (IPD®) Product Code: YM672 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Suplatast tosilate Current Sponsor code: YM672 Other descriptive name: IPD® (Japanese tradename) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Astellas Pharma Europe B.V. | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Germany;Sweden | |||
| 77 | NCT00256542 | January 2006 | 19 February 2015 | Study of U101 for Bladder Pain and/or Urgency | A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin | Pelvic Pain;Interstitial Cystitis;Bladder Diseases | Drug: Alkalinized Lidocaine-Heparin | Urigen | Not recruiting | 18 Years | N/A | Both | 90 | Phase 2 | United States | |
| 78 | EUCTR2005-000890-23-SE | 13/10/2005 | 19 March 2012 | NO as an objective marker for inflammation in patients with interstitial cystitis treated with cyclosporine. | NO as an objective marker for inflammation in patients with interstitial cystitis treated with cyclosporine. | Interstitiell cystit | Trade Name: Sandimmun Neoral Product Name: Sandimmun Neoral Pharmaceutical Form: Capsule* INN or Proposed INN: Ciklosporin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10, 25, 50, 100- | Ingrid Ehrén | Not Recruiting | Female: yes Male: yes | 15 | Sweden | ||||
| 79 | NCT00295854 | May 2005 | 19 October 2017 | Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis | A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis | Interstitial Cystitis | Drug: MN-001 BID;Drug: MN-001;Drug: Placebo | MediciNova | Not recruiting | 18 Years | N/A | All | 296 | Phase 2 | United States | |
| 80 | NCT00124306 | February 2005 | 19 February 2015 | Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS) | A Randomized Multicenter Clinical Trial to Evaluate the Efficacy of Amitriptyline for the Treatment of Painful Bladder Syndrome (PBS) in Newly Diagnosed Patients | Bladder Diseases;Interstitial Cystitis | Drug: Amitriptyline;Other: Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | University of Pennsylvania | Not recruiting | 18 Years | N/A | Both | 271 | Phase 3 | United States;Canada |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 81 | NCT00194610 | May 2004 | 19 October 2017 | Botox as a Treatment for Interstitial Cystitis in Women | Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial | Painful Bladder Syndrome;Interstitial Cystitis | Drug: Botox;Other: normal saline | University of Washington | Paul G. Allen Family Foundation | Not recruiting | 18 Years | N/A | Female | 20 | Phase 4 | United States |
| 82 | NCT00086684 | September 2003 | 19 October 2017 | Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis | Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of ELMIRON for the Treatment of Interstitial Cystitis | Interstitial Cystitis | Drug: Pentosan polysulfate sodium 100 mg;Drug: Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Not recruiting | 18 Years | N/A | All | 369 | Phase 4 | United States;Canada | |
| 83 | NCT00004316 | June 1995 | 19 February 2015 | Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis | Interstitial Cystitis;Vulvar Diseases | Drug: capsaicin | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | University of Pittsburgh | Not recruiting | 18 Years | N/A | Female | 139 | Phase 1/Phase 2 |